Camizestrant vs Tamoxifen (Soltamox)

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

HR+/HER2- Metastatic Breast Cancer

Shared mechanism: Estrogen receptor · full HR+/HER2- Metastatic Breast Cancer pipeline

Camizestrant · Etcamah

Marketed by AstraZeneca

Approved in HR+/HER2- Metastatic Breast Cancersmall molecule
Reliable signal

NCT04964934 · Phase 3 · active, not recruiting

This was a randomized, triple-blinded, placebo-controlled Phase III trial with an active comparator (continued aromatase inhibitor) in 315 patients, using progression-free survival (a hard clinical endpoint) as the primary measure. The result, reported via an external source since CT.gov has not yet posted results, showed a clear and highly statistically significant benefit for camizestrant (median PFS 16.0 vs 9.2 months, HR 0.44, p<0.00001), meeting the primary endpoint in the favorable direction.

Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.

Next expected readout: May 2027 · NCT04644068 (registry estimate)

Reported efficacy

Progression-free survival (PFS) assessed by the Investigator as defined by response evaluation criteria in solid tumors (RECIST version 1.1) (From randomization until the earlier of the progression event or death (approximately 2 years)): SERENA-6 (NCT04964934), primary endpoint PFS: median PFS 16.0 months (camizestrant + CDK4/6i) vs 9.2 months (aromatase inhibitor + CDK4/6i); HR 0.44 (95% CI 0.31-0.60); p<0.00001 (met)

Result source: NCT04964934

Tamoxifen (Soltamox)

Marketed by Mayne Pharma and partners

Approved in HR+/HER2- Metastatic Breast Cancersmall molecule
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

Next expected readout: December 2026 · NCT04174352 (registry estimate)

No aligned efficacy figure on record for this race.

Results for HR+/HER2- Metastatic Breast Cancer

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointCamizestrantTamoxifen (Soltamox)
PFS, median—Trial running · NCT0771745020.2 vs 15.6vs Endocrine Therapyn 173NCT00601900
2 other results
OS, median—Trial running · NCT0771745047.2 vs 43.9vs Endocrine Therapyn 173NCT00601900
1 other result
ORR—Trial running · NCT0771745030%bn 47NCT02668666
Clinical benefit rate—Trial running · NCT0771745064%bn 47NCT02668666

PFS, median

Camizestrant
—Trial running · NCT07717450
Tamoxifen (Soltamox)
20.2 vs 15.6vs Endocrine Therapyn 173NCT00601900
2 other results

OS, median

Camizestrant
—Trial running · NCT07717450
Tamoxifen (Soltamox)
47.2 vs 43.9vs Endocrine Therapyn 173NCT00601900
1 other result

ORR

Camizestrant
—Trial running · NCT07717450
Tamoxifen (Soltamox)
30%bn 47NCT02668666

Clinical benefit rate

Camizestrant
—Trial running · NCT07717450
Tamoxifen (Soltamox)
64%bn 47NCT02668666
  1. b Single-arm result: the trial had no control arm, so the number has no comparator and does not compare with a randomised result.
  2. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  3. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.

Camizestrant
SERENA-6 (NCT04964934), primary endpoint PFS: median PFS 16.0 months (camizestrant + CDK4/6i) vs 9.2 months (aromatase inhibitor + CDK4/6i); HR 0.44 (95% CI 0.31-0.60); p<0.00001 NCT04964934 · Phase 3 · design grade: strong · publication or press release
Percentage Change From Baseline in Estrogen Receptor (ER) Expression Between Pre- and On-treatment Tumour Samples (Primary Analysis) (Baseline (Screening Day -21 to 1) to Biopsy day (Days 5-7 [Stage 1 and 2] or Days 12-15 [Stage 3])): AZD9833 75 mg (Stage 1 + 2) -62.7% (95% CI -67.46--57.93) vs AZD9833 150 mg (Stage 1 + 2) -62.8% (95% CI -67.13--58.43) vs AZD9833 300 mg (Stage 2) -67.1% (95% CI -74.49--59.74) vs AZD9833 75 mg (Stage 3) -66.9% (95% CI -72.34--61.46) vs AZD9833 150 mg (Stage 3) -65.0% (95% CI -70.27--59.81) NCT04588298 · Phase 2 · design grade: weak · reviewed ClinicalTrials.gov result

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. Camizestrant: 4 of 4 rows · Tamoxifen (Soltamox): 4 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricCamizestrantTamoxifen (Soltamox)
Dropout rate
3.3%75 mga
NCT04588298 · Phase 2
show 4 more results
3.3%75 mg
NCT04588298 · Phase 2
7.7%300 mg
NCT04588298 · Phase 2
0%150 mg
NCT04588298 · Phase 2
6.9%150 mg
NCT04588298 · Phase 2
0%a
NCT00601900 · Phase 3 · registry result, not featured evidence · combination
show 13 more results
0.1%
NCT00036270 · Phase 3 · registry result, not featured evidence
0%
NCT02668666 · Phase 2 · registry result, not featured evidence
99.2%
NCT01124695 · Phase 2 · registry result, not featured evidence
10.7%TAK-228 Plus Tamoxifen
NCT02988986 · Phase 2 · registry result, not featured evidence · combination
—TAK-228 and Tamoxifen
NCT02988986 · Phase 2 · registry result, not featured evidence · combination
0%high dose
NCT03045653 · Phase 2 · registry result, not featured evidence
63.2%
NCT00118157 · Phase 2 · registry result, not featured evidence · combination
11.4%
NCT02806544 · Phase 2 · registry result, not featured evidence
0%
NCT00365599 · Phase 2 · registry result, not featured evidence · combination
7.7%
NCT00952731 · Phase 2 · registry result, not featured evidence · combination
—
NCT03280563 · Phase 1/2 · registry result, not featured evidence · combination
0%
NCT02913430 · Phase 1 · registry result, not featured evidence · combination
17.9%
NCT01027416 · Phase na · registry result, not featured evidence
Discontinued due to AEs
0%75 mga
NCT04588298 · Phase 2
show 4 more results
0%75 mg
NCT04588298 · Phase 2
7.7%300 mg
NCT04588298 · Phase 2
0%150 mg
NCT04588298 · Phase 2
6.9%150 mg
NCT04588298 · Phase 2
—a
NCT00601900 · Phase 3 · registry result, not featured evidence · combination
show 13 more results
—
NCT00036270 · Phase 3 · registry result, not featured evidence
—
NCT02668666 · Phase 2 · registry result, not featured evidence
8.9%
NCT01124695 · Phase 2 · registry result, not featured evidence
—TAK-228 Plus Tamoxifen
NCT02988986 · Phase 2 · registry result, not featured evidence · combination
—TAK-228 and Tamoxifen
NCT02988986 · Phase 2 · registry result, not featured evidence · combination
—high dose
NCT03045653 · Phase 2 · registry result, not featured evidence
10.5%
NCT00118157 · Phase 2 · registry result, not featured evidence · combination
—
NCT02806544 · Phase 2 · registry result, not featured evidence
—
NCT00365599 · Phase 2 · registry result, not featured evidence · combination
—
NCT00952731 · Phase 2 · registry result, not featured evidence · combination
—
NCT03280563 · Phase 1/2 · registry result, not featured evidence · combination
—
NCT02913430 · Phase 1 · registry result, not featured evidence · combination
—
NCT01027416 · Phase na · registry result, not featured evidence
Serious AEs
0%75 mga
NCT04588298 · Phase 2
show 4 more results
0%75 mg
NCT04588298 · Phase 2
0%300 mg
NCT04588298 · Phase 2
0%150 mg
NCT04588298 · Phase 2
0%150 mg
NCT04588298 · Phase 2
28.7%a
NCT00601900 · Phase 3 · registry result, not featured evidence · combination
show 13 more results
17.1%
NCT00036270 · Phase 3 · registry result, not featured evidence
32.7%
NCT02668666 · Phase 2 · registry result, not featured evidence
24.6%
NCT01124695 · Phase 2 · registry result, not featured evidence
—TAK-228 Plus Tamoxifen
NCT02988986 · Phase 2 · registry result, not featured evidence · combination
3.6%TAK-228 and Tamoxifen
NCT02988986 · Phase 2 · registry result, not featured evidence · combination
0%high dose
NCT03045653 · Phase 2 · registry result, not featured evidence
100%
NCT00118157 · Phase 2 · registry result, not featured evidence · combination
0%
NCT02806544 · Phase 2 · registry result, not featured evidence
9.3%
NCT00365599 · Phase 2 · registry result, not featured evidence · combination
0%
NCT00952731 · Phase 2 · registry result, not featured evidence · combination
0%
NCT03280563 · Phase 1/2 · registry result, not featured evidence · combination
0%
NCT02913430 · Phase 1 · registry result, not featured evidence · combination
0%
NCT01027416 · Phase na · registry result, not featured evidence
Most frequent reported AEs
75 mga
nausea 13.3%
fatigue 6.7%
headache 6.7%
NCT04588298 · Phase 2
show 4 more results
75 mg
visual impairment 20%
headache 10%
photopsia 10%
NCT04588298 · Phase 2
300 mg
hypertension 23.1%
visual impairment 23.1%
photopsia 15.4%
NCT04588298 · Phase 2
150 mg
visual impairment 15.2%
diplopia 12.1%
photopsia 12.1%
NCT04588298 · Phase 2
150 mg
visual impairment 24.1%
diplopia 17.2%
hypertension 13.8%
NCT04588298 · Phase 2
a
arthralgia 70.3%
hypertension 59%
proteinuria 47.7%
NCT00601900 · Phase 3 · registry result, not featured evidence · combination
show 11 more results
hot flush 31.3%
arthralgia 23.8%
fatigue 16.4%
NCT00036270 · Phase 3 · registry result, not featured evidence
neutrophil count decreased 71.4%
fatigue 65.3%
white blood cell decreased 65.3%
NCT02668666 · Phase 2 · registry result, not featured evidence
fatigue 14.8%
back pain 13.9%
nausea 11.5%
NCT01124695 · Phase 2 · registry result, not featured evidence
nausea 100%
NCT02988986 · Phase 2 · registry result, not featured evidence · combination
high dose
fatigue 23.3%
NCT03045653 · Phase 2 · registry result, not featured evidence
anemia 36.8%
nausea 36.8%
anorexia 31.6%
NCT00118157 · Phase 2 · registry result, not featured evidence · combination
fatigue - grade 2 18.6%
nausea - grade 2 18.6%
anorexia/weight loss - grade 2 16.3%
NCT00365599 · Phase 2 · registry result, not featured evidence · combination
hot flashes 58.3%
pain 41.7%
pain: breast 41.7%
NCT00952731 · Phase 2 · registry result, not featured evidence · combination
arthralgia 33.3%
back pain 33.3%
headache 33.3%
NCT03280563 · Phase 1/2 · registry result, not featured evidence · combination
blood and lymphatic system disorders - other 50%
hypertension 50%
neutrophil count decreased 50%
NCT02913430 · Phase 1 · registry result, not featured evidence · combination
headache 32.1% (placebo 0%)
night sweats 32.1% (placebo 0%)
irritability 28.6% (placebo 0%)
NCT01027416 · Phase na · registry result, not featured evidence

Notes

  1. aPopulation comparability has not been reviewed for these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Tamoxifen (Soltamox)

PFS 20.2 vs 15.6 Endocrine Therapy months
time to event · months
NCT00601900 · Phase 3 · registry result, not featured evidence · combination
PFS-12 73% (n=173) vs 61% (n=170) Endocrine Therapy @ 52wk
responder rate · % of participants
NCT00601900 · Phase 3 · registry result, not featured evidence · combination
PFS 6mo 87% (n=173) vs 77% (n=170) Endocrine Therapy @ 26wk
responder rate · % of participants
NCT00601900 · Phase 3 · registry result, not featured evidence · combination
Overall Survival 47.2 vs 43.9 Endocrine Therapy months
time to event · months
NCT00601900 · Phase 3 · registry result, not featured evidence · combination
Disease Free Survival 352 vs 388 Tamoxifen Followed by Exemestane count @ 143wk
event count · count
NCT00036270 · Phase 3 · registry result, not featured evidence
show 1 more result
712 vs 714 Tamoxifen Followed by Exemestane count @ 260wk
NCT00036270 · Phase 3 · registry result, not featured evidence
Overall Survival 485 vs 476 Tamoxifen Followed by Exemestane count @ 260wk
event count · count
NCT00036270 · Phase 3 · registry result, not featured evidence
Relapse Free Survival 499 vs 521 Tamoxifen Followed by Exemestane count @ 260wk
event count · count
NCT00036270 · Phase 3 · registry result, not featured evidence
PFS 9.13 months
time to event · months
No placebo or comparator arm
NCT02668666 · Phase 2 · registry result, not featured evidence
show 2 more results
5 months @ 156wkhigh dose
NCT03045653 · Phase 2 · registry result, not featured evidence
NA months
NCT02913430 · Phase 1 · registry result, not featured evidence · combination
ORR 30% (n=47)
responder rate · % of participants
No placebo or comparator arm
NCT02668666 · Phase 2 · registry result, not featured evidence
Clinical Benefit 64% (n=47)
responder rate · % of participants
No placebo or comparator arm
NCT02668666 · Phase 2 · registry result, not featured evidence
OS Rate at 12 75.63% (n=49) @ 104wk
responder rate · % of participants
No placebo or comparator arm
NCT02668666 · Phase 2 · registry result, not featured evidence
Pathologic Complete 0% (n=23) @ 16wk
responder rate · % of participants
No placebo or comparator arm
NCT02988986 · Phase 2 · registry result, not featured evidence · combination · converted to % from 0 Participants as posted
show 1 more result
7.7% (n=13)*
NCT02806544 · Phase 2 · registry result, not featured evidence · converted to % from 1 participants as posted

+ 7 further endpoints in the CSV export.

Breast Cancer

Shared mechanism: Estrogen receptor · full Breast Cancer pipeline

Camizestrant · Etcamah

Marketed by AstraZeneca

Approved in Breast Cancersmall molecule
Reliable signal

NCT04964934 · Phase 3 · active, not recruiting

This was a randomized, triple-blinded, placebo-controlled Phase III trial with an active comparator (continued aromatase inhibitor) in 315 patients, using progression-free survival (a hard clinical endpoint) as the primary measure. The result, reported via an external source since CT.gov has not yet posted results, showed a clear and highly statistically significant benefit for camizestrant (median PFS 16.0 vs 9.2 months, HR 0.44, p<0.00001), meeting the primary endpoint in the favorable direction.

Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.

Next expected readout: April 2027 · NCT05774951 (registry estimate)

Reported efficacy

Progression-free survival (PFS) assessed by the Investigator as defined by response evaluation criteria in solid tumors (RECIST version 1.1) (From randomization until the earlier of the progression event or death (approximately 2 years)): SERENA-6 (NCT04964934), primary endpoint PFS: median PFS 16.0 months (camizestrant + CDK4/6i) vs 9.2 months (aromatase inhibitor + CDK4/6i); HR 0.44 (95% CI 0.31-0.60); p<0.00001 (met)

Result source: NCT04964934

Tamoxifen (Soltamox)

Marketed by Mayne Pharma and partners

Approved in Breast Cancersmall molecule
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

Next expected readout: December 2026 · NCT04174352 (registry estimate)

Reported efficacy

Disease-free Survival (5-year estimates, reported at a median follow-up of 67 months.): Disease-free Survival (5-year estimates, reported at a median follow-up of 67 months.): T+OFS 86.6% (95% CI 84.2 to 88.7) | E+OFS 89% (95% CI 86.8 to 90.9) vs Tamoxifen 84.7% (95% CI 82.2 to 86.9) (mixed)

Result source: NCT00066690

Results for Breast Cancer

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.

Camizestrant
SERENA-6 (NCT04964934), primary endpoint PFS: median PFS 16.0 months (camizestrant + CDK4/6i) vs 9.2 months (aromatase inhibitor + CDK4/6i); HR 0.44 (95% CI 0.31-0.60); p<0.00001 NCT04964934 · Phase 3 · design grade: strong · publication or press release
Percentage Change From Baseline in Estrogen Receptor (ER) Expression Between Pre- and On-treatment Tumour Samples (Primary Analysis) (Baseline (Screening Day -21 to 1) to Biopsy day (Days 5-7 [Stage 1 and 2] or Days 12-15 [Stage 3])): AZD9833 75 mg (Stage 1 + 2) -62.7% (95% CI -67.46--57.93) vs AZD9833 150 mg (Stage 1 + 2) -62.8% (95% CI -67.13--58.43) vs AZD9833 300 mg (Stage 2) -67.1% (95% CI -74.49--59.74) vs AZD9833 75 mg (Stage 3) -66.9% (95% CI -72.34--61.46) vs AZD9833 150 mg (Stage 3) -65.0% (95% CI -70.27--59.81) NCT04588298 · Phase 2 · design grade: weak · reviewed ClinicalTrials.gov result

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

Coverage. Camizestrant: 4 of 4 rows · Tamoxifen (Soltamox): 4 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricCamizestrantTamoxifen (Soltamox)
Dropout rate
3.3%75 mga
NCT04588298 · Phase 2
show 4 more results
3.3%75 mg
NCT04588298 · Phase 2
7.7%300 mg
NCT04588298 · Phase 2
0%150 mg
NCT04588298 · Phase 2
6.9%150 mg
NCT04588298 · Phase 2
29.6%E+OFSa
NCT00066690 · Phase 3 · registry result, not featured evidence · combination
show 17 more results
26.7%T+OFS
NCT00066690 · Phase 3 · registry result, not featured evidence · combination
0%
NCT00601900 · Phase 3 · registry result, not featured evidence · combination
10%TC (Tamoxifen Control)
NCT00295646 · Phase 3 · registry result, not featured evidence
9.1%TZ (Tamoxifen+Zoledronate)
NCT00295646 · Phase 3 · registry result, not featured evidence · combination
0%
NCT02668666 · Phase 2 · registry result, not featured evidence
99.2%
NCT01124695 · Phase 2 · registry result, not featured evidence
3.2%Exemestane
NCT01831076 · Phase 2 · registry result, not featured evidence
20%Exemestane Plus Tamoxifen
NCT01831076 · Phase 2 · registry result, not featured evidence · combination
10.7%TAK-228 Plus Tamoxifen
NCT02988986 · Phase 2 · registry result, not featured evidence · combination
—TAK-228 and Tamoxifen
NCT02988986 · Phase 2 · registry result, not featured evidence · combination
0%high dose
NCT03045653 · Phase 2 · registry result, not featured evidence
0%
NCT01614210 · Phase 2 · registry result, not featured evidence
63.2%
NCT00118157 · Phase 2 · registry result, not featured evidence · combination
11.4%
NCT02806544 · Phase 2 · registry result, not featured evidence
0%
NCT00365599 · Phase 2 · registry result, not featured evidence · combination
7.7%
NCT00952731 · Phase 2 · registry result, not featured evidence · combination
17.6%
NCT00499083 · Phase 2 · registry result, not featured evidence
Discontinued due to AEs
0%75 mga
NCT04588298 · Phase 2
show 4 more results
0%75 mg
NCT04588298 · Phase 2
7.7%300 mg
NCT04588298 · Phase 2
0%150 mg
NCT04588298 · Phase 2
6.9%150 mg
NCT04588298 · Phase 2
13.2%E+OFSa
NCT00066690 · Phase 3 · registry result, not featured evidence · combination
show 17 more results
6.8%T+OFS
NCT00066690 · Phase 3 · registry result, not featured evidence · combination
—
NCT00601900 · Phase 3 · registry result, not featured evidence · combination
—TC (Tamoxifen Control)
NCT00295646 · Phase 3 · registry result, not featured evidence
—TZ (Tamoxifen+Zoledronate)
NCT00295646 · Phase 3 · registry result, not featured evidence · combination
—
NCT02668666 · Phase 2 · registry result, not featured evidence
8.9%
NCT01124695 · Phase 2 · registry result, not featured evidence
—Exemestane
NCT01831076 · Phase 2 · registry result, not featured evidence
—Exemestane Plus Tamoxifen
NCT01831076 · Phase 2 · registry result, not featured evidence · combination
—TAK-228 Plus Tamoxifen
NCT02988986 · Phase 2 · registry result, not featured evidence · combination
—TAK-228 and Tamoxifen
NCT02988986 · Phase 2 · registry result, not featured evidence · combination
—high dose
NCT03045653 · Phase 2 · registry result, not featured evidence
—
NCT01614210 · Phase 2 · registry result, not featured evidence
10.5%
NCT00118157 · Phase 2 · registry result, not featured evidence · combination
—
NCT02806544 · Phase 2 · registry result, not featured evidence
—
NCT00365599 · Phase 2 · registry result, not featured evidence · combination
—
NCT00952731 · Phase 2 · registry result, not featured evidence · combination
—
NCT00499083 · Phase 2 · registry result, not featured evidence
Serious AEs
0%75 mga
NCT04588298 · Phase 2
show 4 more results
0%75 mg
NCT04588298 · Phase 2
0%300 mg
NCT04588298 · Phase 2
0%150 mg
NCT04588298 · Phase 2
0%150 mg
NCT04588298 · Phase 2
37.5%E+OFSa
NCT00066690 · Phase 3 · registry result, not featured evidence · combination
show 17 more results
37.2%T+OFS
NCT00066690 · Phase 3 · registry result, not featured evidence · combination
28.7%
NCT00601900 · Phase 3 · registry result, not featured evidence · combination
20.7%TC (Tamoxifen Control)
NCT00295646 · Phase 3 · registry result, not featured evidence
22.9%TZ (Tamoxifen+Zoledronate)
NCT00295646 · Phase 3 · registry result, not featured evidence · combination
32.7%
NCT02668666 · Phase 2 · registry result, not featured evidence
24.6%
NCT01124695 · Phase 2 · registry result, not featured evidence
0%Exemestane
NCT01831076 · Phase 2 · registry result, not featured evidence
0%Exemestane Plus Tamoxifen
NCT01831076 · Phase 2 · registry result, not featured evidence · combination
—TAK-228 Plus Tamoxifen
NCT02988986 · Phase 2 · registry result, not featured evidence · combination
3.6%TAK-228 and Tamoxifen
NCT02988986 · Phase 2 · registry result, not featured evidence · combination
0%high dose
NCT03045653 · Phase 2 · registry result, not featured evidence
1.9%
NCT01614210 · Phase 2 · registry result, not featured evidence
100%
NCT00118157 · Phase 2 · registry result, not featured evidence · combination
0%
NCT02806544 · Phase 2 · registry result, not featured evidence
9.3%
NCT00365599 · Phase 2 · registry result, not featured evidence · combination
0%
NCT00952731 · Phase 2 · registry result, not featured evidence · combination
33.3%
NCT00499083 · Phase 2 · registry result, not featured evidence
Most frequent reported AEs
75 mga
nausea 13.3%
fatigue 6.7%
headache 6.7%
NCT04588298 · Phase 2
show 4 more results
75 mg
visual impairment 20%
headache 10%
photopsia 10%
NCT04588298 · Phase 2
300 mg
hypertension 23.1%
visual impairment 23.1%
photopsia 15.4%
NCT04588298 · Phase 2
150 mg
visual impairment 15.2%
diplopia 12.1%
photopsia 12.1%
NCT04588298 · Phase 2
150 mg
visual impairment 24.1%
diplopia 17.2%
hypertension 13.8%
NCT04588298 · Phase 2
a
hot flashes/flushes 81.9%
pain - joint 77.7%
fatigue (asthenia, lethargy, malaise) 59%
NCT00066690 · Phase 3 · registry result, not featured evidence · combination
show 13 more results
hot flashes/flushes 80%
pain - joint 69.5%
sweating (diaphoresis) 61.7%
NCT00066690 · Phase 3 · registry result, not featured evidence · combination
arthralgia 70.3%
hypertension 59%
proteinuria 47.7%
NCT00601900 · Phase 3 · registry result, not featured evidence · combination
other/minor (not categorized) 24%
bone pain 20.9%
fatigue 15.6%
NCT00295646 · Phase 3 · registry result, not featured evidence
bone pain 29.3%
other/minor (not categorized) 24.9%
fatigue 18.2%
NCT00295646 · Phase 3 · registry result, not featured evidence · combination
neutrophil count decreased 71.4%
fatigue 65.3%
white blood cell decreased 65.3%
NCT02668666 · Phase 2 · registry result, not featured evidence
fatigue 14.8%
back pain 13.9%
nausea 11.5%
NCT01124695 · Phase 2 · registry result, not featured evidence
nausea 100%
NCT02988986 · Phase 2 · registry result, not featured evidence · combination
high dose
fatigue 23.3%
NCT03045653 · Phase 2 · registry result, not featured evidence
hot flashes 36.5%
nausea 21.2%
fatigue 9.6%
NCT01614210 · Phase 2 · registry result, not featured evidence
anemia 36.8%
nausea 36.8%
anorexia 31.6%
NCT00118157 · Phase 2 · registry result, not featured evidence · combination
fatigue - grade 2 18.6%
nausea - grade 2 18.6%
anorexia/weight loss - grade 2 16.3%
NCT00365599 · Phase 2 · registry result, not featured evidence · combination
hot flashes 58.3%
pain 41.7%
pain: breast 41.7%
NCT00952731 · Phase 2 · registry result, not featured evidence · combination
bone pain 33.3%
hypokalemia 33.3%
mucositis oral 33.3%
NCT00499083 · Phase 2 · registry result, not featured evidence

Notes

  1. aPopulation comparability has not been reviewed for these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Tamoxifen (Soltamox)

Disease-free Survival 86.6% (n=1015) vs 84.7% (n=1018) Tamoxifen @ 260wk
responder rate · % of participants
NCT00066690 · Phase 3 · registry result, not featured evidence · combination
show 1 more result
89% (n=1014) vs 84.7% (n=1018) Tamoxifen @ 260wk
NCT00066690 · Phase 3 · registry result, not featured evidence · combination
Breast Cancer-free Interval 88.4% (n=1015) vs 86.4% (n=1018) Tamoxifen @ 260wk
responder rate · % of participants
NCT00066690 · Phase 3 · registry result, not featured evidence · combination
show 1 more result
90.9% (n=1014) vs 86.4% (n=1018) Tamoxifen @ 260wk
NCT00066690 · Phase 3 · registry result, not featured evidence · combination
Distant Recurrence-free Interval 91.3% (n=1015) vs 90.7% (n=1018) Tamoxifen @ 260wk
responder rate · % of participants
NCT00066690 · Phase 3 · registry result, not featured evidence · combination
show 1 more result
93% (n=1014) vs 90.7% (n=1018) Tamoxifen @ 260wk
NCT00066690 · Phase 3 · registry result, not featured evidence · combination
Overall Survival 93.3% (n=1015) vs 91.5% (n=1018) Tamoxifen @ 416wk
responder rate · % of participants
NCT00066690 · Phase 3 · registry result, not featured evidence · combination
show 1 more result
92.1% (n=1014) vs 91.5% (n=1018) Tamoxifen @ 416wk
NCT00066690 · Phase 3 · registry result, not featured evidence · combination
PFS 20.2 vs 15.6 Endocrine Therapy months
time to event · months
NCT00601900 · Phase 3 · registry result, not featured evidence · combination
PFS-12 73% (n=173) vs 61% (n=170) Endocrine Therapy @ 52wk
responder rate · % of participants
NCT00601900 · Phase 3 · registry result, not featured evidence · combination
PFS 6mo 87% (n=173) vs 77% (n=170) Endocrine Therapy @ 26wk
responder rate · % of participants
NCT00601900 · Phase 3 · registry result, not featured evidence · combination
Overall Survival 47.2 vs 43.9 Endocrine Therapy months
time to event · months
NCT00601900 · Phase 3 · registry result, not featured evidence · combination
show 4 more results
NA vs NA Anastrozole months
NCT00295646 · Phase 3 · registry result, not featured evidence · combination
NA vs NA Anastrozole months
NCT00295646 · Phase 3 · registry result, not featured evidence
NA vs NA Anastrozole months
NCT00295646 · Phase 3 · registry result, not featured evidence · combination
NA vs NA Anastrozole months
NCT00295646 · Phase 3 · registry result, not featured evidence
Disease-free Survival NA vs NA Anastrozole months
time to event · months
NCT00295646 · Phase 3 · registry result, not featured evidence · combination
show 3 more results
NA vs NA Anastrozole months
NCT00295646 · Phase 3 · registry result, not featured evidence
NA vs NA Anastrozole months
NCT00295646 · Phase 3 · registry result, not featured evidence · combination
NA vs NA Anastrozole months
NCT00295646 · Phase 3 · registry result, not featured evidence
Recurrence-free Survival NA vs NA Anastrozole months
time to event · months
NCT00295646 · Phase 3 · registry result, not featured evidence · combination
show 3 more results
NA vs NA Anastrozole months
NCT00295646 · Phase 3 · registry result, not featured evidence
NA vs NA Anastrozole months
NCT00295646 · Phase 3 · registry result, not featured evidence · combination
NA vs NA Anastrozole months
NCT00295646 · Phase 3 · registry result, not featured evidence
PFS 9.13 months
time to event · months
No placebo or comparator arm
NCT02668666 · Phase 2 · registry result, not featured evidence
show 1 more result
5 months @ 156wkhigh dose
NCT03045653 · Phase 2 · registry result, not featured evidence
ORR 30% (n=47)
responder rate · % of participants
No placebo or comparator arm
NCT02668666 · Phase 2 · registry result, not featured evidence

+ 10 further endpoints in the CSV export.

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Camizestrant's landscape · Tamoxifen (Soltamox)'s landscape